Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients

Faouzi Djebbari¹, Alexandros Rampotas^{1

2}, Grant Vallance¹, Fotios Panitsas³, Nanda Basker⁴, Gina Sangha⁵, Beena Salhan^{6

7

8

9}, Farheen Karim^{9

10}, Firas Al-Kaisi¹¹, Amy Gudger^{9

12}, Loretta Ngu¹³, Matt Poynton¹⁴, Ho Pui Jeff Lam¹⁵, Lowri Morgan¹⁶, Laura Yang¹⁷, Jennifer Young¹⁸, Mairi Walker¹⁹, Ismini Tsagkaraki²⁰, Laura Anderson²¹, Saleena Rani Chauhan^{9

22}, Rebecca Maddams²³, Richard Soutar²⁴, Margarita Triantafillou²⁵, Steve Prideaux²⁶, Abubaker Obeidalla²⁷, Toby A Eyre¹, Ceri Bygrave¹⁶, Jaimal Kothari¹, Supratik Basu^{9

10

28}, Karthik Ramasamy¹

Affiliations

¹ Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
² Oxford University Clinical Academic Graduate School, Oxford, UK.
³ Department of Haematology, Laiko General Hospital, Athens, Greece.
⁴ University Hospital Southampton, Southampton, UK.
⁵ Milton Keynes Hospital, Milton Keynes, UK.
⁶ Birmingham Heartlands Hospital, Birmingham, UK.
⁷ Good Hope Hospital, Birmingham, UK.
⁸ Solihull Hospital, Birmingham, UK.
⁹ West Midlands Research Consortium (WMRC), West Midlands, UK.
¹⁰ The Royal Wolverhampton NHS Trust, Wolverhampton, UK.
¹¹ Royal Derby Hospital, Derby, UK.
¹² Queen Elizabeth Hospital, Birmingham, UK.
¹³ Royal Devon & Exeter NHS Foundation Trust, Exeter, UK.
¹⁴ Royal Berkshire Hospital, Reading, UK.
¹⁵ Guy's and St Thomas NHS Foundation Trust, London, UK.
¹⁶ University Hospital of UK, London, UK.
¹⁷ University Hospitals Sussex NHS Foundation Trust, Chichester, UK.
¹⁸ Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
¹⁹ University Hospital Crosshouse, Crosshouse, UK.
²⁰ Stoke Mandeville Hospital, Aylesbury, UK.
²¹ Royal United Hospital Bath, Bath, UK.
²² Worcestershire Acute Hospitals NHS Trust, Worcester, UK.
²³ Poole Hospital, Poole, UK.
²⁴ Beatson Oncology Centre, Glasgow, UK.
²⁵ Manchester Royal Infirmary, Manchester, UK.
²⁶ Great Western Hospital, Swindon, UK.
²⁷ Wexham Park Hospital, Slough, UK.
²⁸ University of Wolverhampton, Wolverhampton, UK.

Faouzi Djebbari et al. Br J Haematol. 2023 Apr.

. 2023 Apr;201(1):162-167.

doi: 10.1111/bjh.18672. Epub 2023 Jan 31.

¹ Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
² Oxford University Clinical Academic Graduate School, Oxford, UK.
³ Department of Haematology, Laiko General Hospital, Athens, Greece.
⁴ University Hospital Southampton, Southampton, UK.
⁵ Milton Keynes Hospital, Milton Keynes, UK.
⁶ Birmingham Heartlands Hospital, Birmingham, UK.
⁷ Good Hope Hospital, Birmingham, UK.
⁸ Solihull Hospital, Birmingham, UK.
⁹ West Midlands Research Consortium (WMRC), West Midlands, UK.
¹⁰ The Royal Wolverhampton NHS Trust, Wolverhampton, UK.
¹¹ Royal Derby Hospital, Derby, UK.
¹² Queen Elizabeth Hospital, Birmingham, UK.
¹³ Royal Devon & Exeter NHS Foundation Trust, Exeter, UK.
¹⁴ Royal Berkshire Hospital, Reading, UK.
¹⁵ Guy's and St Thomas NHS Foundation Trust, London, UK.
¹⁶ University Hospital of UK, London, UK.
¹⁷ University Hospitals Sussex NHS Foundation Trust, Chichester, UK.
¹⁸ Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
¹⁹ University Hospital Crosshouse, Crosshouse, UK.
²⁰ Stoke Mandeville Hospital, Aylesbury, UK.
²¹ Royal United Hospital Bath, Bath, UK.
²² Worcestershire Acute Hospitals NHS Trust, Worcester, UK.
²³ Poole Hospital, Poole, UK.
²⁴ Beatson Oncology Centre, Glasgow, UK.
²⁵ Manchester Royal Infirmary, Manchester, UK.
²⁶ Great Western Hospital, Swindon, UK.
²⁷ Wexham Park Hospital, Slough, UK.
²⁸ University of Wolverhampton, Wolverhampton, UK.

No abstract available

Keywords: frailty; isatuximab; myeloma; pomalidomide; real-world.

References

1. Cancer Research UK. Cancer Statistics: myeloma incidence statistics. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/st.... Accessed December 4, 2022.
1. Engelhardt M, Ihorst G, Duque-Afonso J, Wedding U, Spät-Schwalbe E, Goede V, et al. Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. Haematologica. 2020;105(5):1183-8.
1. Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125:2068-74.
1. Engelhardt M, Dold SM, Ihorst G, Zober A, Möller M, Reinhardt H, et al. Geriatric assessment in multiple myeloma patients: validation of the international myeloma working group (IMWG) score and comparison with other common comorbidity scores. Haematologica. 2016;101:1110-9.
1. Engelhardt M, Domm A-S, Dold SM, et al. A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102(5):910.